Universities Allied for Essential Medicines (UAEM) is a promising and inspiring international student network focusing on access to medicines and biomedical innovation. They have a strong presence in the US and Germany and are growing all over Europe with…
Patients before Patents – Response to The Economist by MSF and Oxfam
Protect patients, not patents SIR – You argued that “protection should not be weakened” on pharmaceutical patents (“The new drugs war”, January 4th). Drug patents protect drug-companies’ profits, not patients. The industry promotes several myths to justify its outlandish…
FOR A TRANSPARENT, INNOVATIVE AND JUST RESPONSE TO THE CRISIS IN SPANISH PUBLIC HEALTHCARE”
NEW EXPERT AND CIVIL SOCIETY WORKING GROUP LAUNCH The Working Group on Health, Medicines, and Innovation has been launched with the goal of offering inclusive and constructive recommendations on the evaluation of health access, transparency, the management of expensive patented…
Civil Society demands fair solutions to Greek health crisis
There is a fully-fledged access to health care crisis in Greece as a result of the Troika-dictated cuts over the past four years. Three million people or more, exact figures are hard to get due to “Greek statistics”, have…
Notes from a generally non-informative “civil society” meeting on TTIP
Brief chronicle of an obscure, scarcely informative “civil society” meeting on the TransAtlantic Trade and Investment Partnership in Brussels on January 14th, 2014 A few tidbits of Commission statements: The European Court of Justice might “not be…
Big Pharma´s leaked wish list for TTIP EU-US trade pact
PhRMA/EFPIA priorities for TTIP. I. Regulatory issues : Greater regulatory convergence: Ø a built-in agenda allowing for progressive greater regulatory convergence over time. Ø a Working Group on Pharmaceutical and Medical Devices as platform to discuss implementation issues and address…